Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

TY - JOUR

T1 - Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

AU - Giesen, Nicola

AU - Sprute, Rosanne

AU - Rüthrich, Maria

AU - Khodamoradi, Yascha

AU - Mellinghoff, Sibylle C

AU - Beutel, Gernot

AU - Lueck, Catherina

AU - Koldehoff, Michael

AU - Hentrich, Marcus

AU - Sandherr, Michael

AU - von Bergwelt-Baildon, Michael

AU - Wolf, Hans-Heinrich

AU - Hirsch, Hans H

AU - Wörmann, Bernhard

AU - Cornely, Oliver A

AU - Köhler, Philipp

AU - Schalk, Enrico

AU - von Lilienfeld-Toal, Marie

N1 - Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2020/11

Y1 - 2020/11

N2 - Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria.

AB - Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria.

KW - Antineoplastic Agents/therapeutic use

KW - Betacoronavirus/isolation & purification

KW - COVID-19

KW - Coronavirus Infections/complications

KW - Delivery of Health Care/standards

KW - Disease Management

KW - Evidence-Based Practice/standards

KW - Germany/epidemiology

KW - Humans

KW - Neoplasms/drug therapy

KW - Pandemics

KW - Pneumonia, Viral/complications

KW - Practice Guidelines as Topic/standards

KW - Prognosis

KW - SARS-CoV-2

KW - Societies, Medical

U2 - 10.1016/j.ejca.2020.09.009

DO - 10.1016/j.ejca.2020.09.009

M3 - SCORING: Journal article

C2 - 33068941

VL - 140

SP - 86

EP - 104

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -